Depressed patients perception of the efficacy of electroconvulsive therapy and venlafaxine therapy

Neuroendocrinology Letters

Volumn 28, Issue 6, 2007, Pages 889-894

  Kopeček, Miloslav ^a,b,c   Černá, Lubica ^a   Šulak, Jan ^a,b   Raszka, Michal ^a,b   Bareš, Martin ^a,b   Seifertová, Dagmar ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar depression; Depressive disorder; ECT; Self report inventories; Venlafaxine

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DOSULEPIN; ESCITALOPRAM; HYDROXYZINE; LAMOTRIGINE; LITHIUM; MAPROTILINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; ELECTRODERMAL RESPONSE; FEMALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL HEALTH; MOUSE; NONHUMAN; PATIENT SATISFACTION; PSYCHOLOGIC ASSESSMENT; SELF EVALUATION; TREATMENT RESPONSE;

EID: 37849007687     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Baghai TC, Marcuse A, Brosch M, Schule C, Eser D, et al. 2006. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 7: 82-90.
2. Beck AT, Beck RW. 1972. Screening depressed patients in family practice. A rapid technic. Postgrad Med 52: 81-5.
3. Beck AT, Rial WY, Rickels K. 1974. Short form of depression inventory: cross-validation. Psychol Rep 34: 1184-6.
4. Beck AT, Steer RA. 1990. Beck Anxiety Inventory Manual. San Antonio, TX: The Psychological Corporation.
5. Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, et al. 2001. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 3: 95-104.
6. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. 2002. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - preliminary report. Biol Psychiatry 51: 687-90.
7. ECT study group. 2003. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361: 799-808.
8. Fink M, Taylor MA. 2007. Electroconvulsive therapy: evidence and challenges. JAMA 298: 330-2.
9. Grunhaus L, Schreiber S, Dolberg OT, Hirshman S, Dannon PN. 2002. Response to ECT in major depression: are there differences between unipolar and bipolar depression? Bipolar Disord 4 Suppl 1: 91-3.
10. Husain MM, Rush AJ, Fink M, Knapp B, Petrides G, et al. 2004. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 65: 485-91.
11. Janicak PG, Dowd SM, Martis B, Alam D, Beedle D, et al. 2002. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biol Psychiatry 51: 659-67.
12. Keller MB. 2003. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. Jama 289: 3152-60.
13. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, et al. 2006. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Etectroconvulsive Therapy (CORE). Arch Gen Psychiatry 63: 1337-44.
14. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. 2007. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 31: 574-7.
15. Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. 2003. A meta-analysis of electroconvulsive therapy efficacy in depression. J Ect 19: 139-47.
16. Kho KH, Zwinderman AH, Blansjaar BA. 2005. Predictors for the efficacy of electroconvulsive therapy: chart review of a naturalistic study. J Clin Psychiatry 66: 894-9.
17. Kopecek M, Bares M, Horacek J, Mohr P. 2006. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. Neuroendocrinol Lett 27: 803-6.
18. Kopecek M, Bares M, Mohr P. 2005. Ziprasidone-induced galactorrhea: a case report. Neuroendocrinol Lett 26: 69-70.
19. Kopecek M, Bares M, Seifertova D. 2005. Efficacy of ECT in the treatment of pharmacoresistant depressive disorder from patient point of view (in Czech). Psychiatrie 9: 282-5.
20. Kopecek M, Bares M, Svarc J, Dockery C, Horacek J. 2004. Hyperprolactinemia after low dose of amisulpride. Neuroendocrinol Lett 25: 419-22.
21. Love AW, Grabsch B, Clarke DM, Bloch S, Kissane DW. 2004. Screening for depression in women with metastatic breast cancer: a comparison of the Beck Depression Inventory Short Form and the Hospital Anxiety and Depression Scale. Aust N Z J Psychiatry 38: 526-31.
22. McCall WV. 2007. What does Star*D tell us about ECT? J ECT 23: 1-2.
23. McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, et al. 2007. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess 11: 1-54.
24. Murray CJ, Lopez AD, Jamison DT. 1994. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 72: 495-509.
25. Nemeroff CB. 2007. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68 Suppl 8: 17-25.
26. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, et al. 2006. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163: 210-6.
27. Pagnin D, de Queiroz V, Pini S, Cassano GB. 2004. Efficacy of ECT in depression: a meta-analytic review. J Ect 20: 13-20.
28. Papakostas GI, Shelton RC, Smith J, Fava M. 2007. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68: 826-31.
29. Papakostas GI, Thase ME, Fava M, Craig Nelson J, Shelton RC. 2007. Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biol Psychiatry.
30. Posternak MA, Zimmerman M. 2005. Is there a delay in the anti-depressant effect? A meta-analysis. J Clin Psychiatry 66: 148-58.
31. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, et al. 1996. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 153: 985-92.
32. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. 2004. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 55: 301-12.
33. Rosa MA, Gattaz WF, Pascual-Leone A, Fregni F, Rosa MO, et al. 2006. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. Int J Neuropsychopharmacol 9: 667-76.
34. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. 2006. Acute and longer-term outcomes in depressed out-patients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-17.
35. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, et al. 2006. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354: 1231-42.
36. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, et al. 2001. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285: 1299-307.
37. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, et al. 2007. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711-22.
38. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, Falkai P, Wagner M. 2005. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry 186: 410-6.
39. Stukenberg TW, Dura JR, Kiecolt-Glaser JK. 1990. Depression Screening Scale Validation in an Eldery, Community-Dwelling Population. Psychological Assessment: A Journal of Consulting and Clinical Psychology 2: 134-8.
40. Thase ME. 2003. New approaches to managing difficult-to-treat depressions. J Clin Psychiatry 64 Suppl 1: 3-4.
41. Thase ME, Entsuah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234-41.
42. van den Broek WW, de Lely A, Mulder PG, Birkenhager TK, Bruijn JA. 2004. Effect of antidepressant medication resistance on short-term response to electroconvulsive therapy. J Clin Psychopharmacol 24: 400-3.
43. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, et al. 2007. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 98: 247-52.